News
NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...
Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...
Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...
Novo Nordisk A/S (NYSE:NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which may have violated ...
Diabetes drug Ozempic and weight-loss jab Wegovy may also reduce the risk of dementia, according to a new study. American ...
If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...
Institute of Human Anatomy - IOHA on MSN4h
Ozempic & Wegovy: How They Work and What You Need to KnowLearn about Ozempic and Wegovy, two medications making waves in weight management. Discover how they work, their benefits, ...
Supermarkets are selling fewer groceries thanks to an uptick in Brits taking weight-loss drugs including Wegovy and Mounjaro, ...
A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...
A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.
A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk in older ...
A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results